 Deoxycytidine
"Deoxycytidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE.
| Descriptor ID |
D003841
|
| MeSH Number(s) |
D03.383.742.680.245.500 D13.570.230.329 D13.570.685.245.500
|
| Concept/Terms |
Deoxycytidine- Deoxycytidine
- Cytosine Deoxyribonucleoside
- Deoxyribonucleoside, Cytosine
- Cytosine Deoxyriboside
- Deoxyriboside, Cytosine
|
Below are MeSH descriptors whose meaning is more general than "Deoxycytidine".
Below are MeSH descriptors whose meaning is more specific than "Deoxycytidine".
This graph shows the total number of publications written about "Deoxycytidine" by people in this website by year, and whether "Deoxycytidine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 1 | 3 | | 1998 | 1 | 1 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 2 | 0 | 2 | | 2003 | 3 | 0 | 3 | | 2004 | 4 | 1 | 5 | | 2006 | 4 | 1 | 5 | | 2007 | 4 | 0 | 4 | | 2008 | 4 | 4 | 8 | | 2009 | 1 | 0 | 1 | | 2010 | 6 | 6 | 12 | | 2011 | 0 | 3 | 3 | | 2012 | 2 | 5 | 7 | | 2013 | 2 | 2 | 4 | | 2014 | 0 | 6 | 6 | | 2015 | 3 | 3 | 6 | | 2016 | 1 | 2 | 3 | | 2017 | 1 | 4 | 5 | | 2018 | 0 | 1 | 1 | | 2019 | 1 | 3 | 4 | | 2020 | 4 | 1 | 5 | | 2021 | 1 | 1 | 2 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 2 | 2 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Deoxycytidine" by people in Profiles.
-
Lerner SP, McConkey DJ, Tangen CM, Meeks JJ, Flaig TW, Hua X, Daneshmand S, Alva AS, Lucia MS, Theodorescu D, Goldkorn A, Milowsky MI, Choi W, Bangs R, Gustafson DL, Plets M, Thompson IM. Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449.
-
Stoop TF, Theijse RT, Seelen LWF, Groot Koerkamp B, van Eijck CHJ, Wolfgang CL, van Tienhoven G, van Santvoort HC, Molenaar IQ, Wilmink JW, Del Chiaro M, Katz MHG, Hackert T, Besselink MG. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024 Feb; 21(2):101-124.
-
Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM, Lerner SP. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 09; 84(3):341-347.
-
Hidalgo M, Garcia-Carbonero R, Lim KH, Messersmith WA, Garrido-Laguna I, Borazanci E, Lowy AM, Medina Rodriguez L, Laheru D, Salvador-Barbero B, Malumbres M, Shields DJ, Grossman JE, Huang X, Tammaro M, Martini JF, Yu Y, Kern K, Macarulla T. A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. Cancer Res Commun. 2022 11; 2(11):1326-1333.
-
Ono Y, Inoue Y, Ito H, Sasaki T, Takeda T, Ozaka M, Sasahira N, Hiratsuka M, Matsueda K, Oba A, Sato T, Saiura A, Takahashi Y. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels. HPB (Oxford). 2023 01; 25(1):100-108.
-
Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy? Ann Surg Oncol. 2022 08; 29(8):5051-5052.
-
Ross RB, Rabinovitch RA. Radiation recall after COVID-19 infection. Lancet Oncol. 2022 04; 23(4):e197.
-
Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol. 2022 Aug; 29(8):5038-5050.
-
Walsh CS, Kamrava M, Rogatko A, Kim S, Li A, Cass I, Karlan B, Rimel BJ. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS One. 2021; 16(6):e0252665.
-
Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol. 2021 08 01; 39(22):2486-2496.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|